Sector News

Activist hedge fund angles for Shire breakup to revive struggling shares

October 16, 2017
Life sciences

Shire has hinted that a spinoff of its neuroscience unit may be in the works. But one U.S. hedge fund wants more.

Sachem Head Capital Management, which nabbed a small Shire stake over the summer, is demanding a list of divestments at the Dublin drugmaker, the U.K.’s Sky News reports.

The fund, founded by Bill Ackman protégé Scott Ferguson, hasn’t yet formally penned a letter to the company’s board, but it’s raised the possibility of a larger breakup during discussions with Shire in recent months, Sky’s sources say.

Sachem Head’s urging comes during a rocky period for Shire shares, which have taken a beating since the company doled out $32 billion for hemophilia specialist Baxalta. While executives have touted the merger’s success—and Shire’s progress toward a $700 million cost-savings target—“neither markets nor employees seem as confident as management that things are on track,” UBS analysts wrote in August as they slashed their 12-month price target.

And speaking of executives, their ranks at Shire have thinned recently with the departures of R&D chief Phil Vickers and CFO Jeff Poulton—and those exits haven’t helped shares, either. “The timing is highly inopportune and serves to exacerbate already negative investor sentiment,” Jefferies analyst David Steinberg wrote to clients after the Poulton announcement in August.

Shire has signaled that it may be down for at least a little bit of move-making, revealing in August that it’s “assessing strategic options” for the neuro franchise, which includes the company’s flagship ADHD products. The Irish pharma expects its evaluation to wrap by year’s end.

Meanwhile, divestments across the pharma industry continue. Pfizer last week said it’s considering selling off its consumer health unit, and AstraZeneca has notably been selling off drug rights and striking partnerships as it focuses on its core goals.

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

January 15, 2022

Colorcon Ventures invests in AI-Driven bio-simulation company VeriSIM Life

Life sciences

Colorcon Ventures, the corporate venture fund of Colorcon Inc., has invested in VeriSIM Life, a San Francisco-based startup with a digital bio-simulation platform that accelerates drug development and reduces animal testing.

January 15, 2022

A record number of biotechs are going public. Here’s how they’re performing.

Life sciences

Initial public offerings have fueled biotech’s boom. Keep track of them as they happen with this database. Which biotechs create value over time, and which fail? What types of companies are generating the best returns? Who are their top investors? Biopharma Dive is tracking these details in the database which will be updated regularly.

January 15, 2022

Sanofi cuts ties with Sangamo, sharpening focus on ‘off-the-shelf’ cell therapy

Life sciences

Sanofi has ended a long-running alliance with Sangamo Therapeutics to develop genetic medicines for inherited blood disorders, among them an experimental sickle cell disease therapy that is in early clinical testing.
The two have been developing complex, personalized treatments, led by a sickle cell drug known as SAR445136. But Sanofi is now more interested in off-the-shelf approaches, which are meant to be more convenient.

Send this to a friend